3195-65-1

Basic information

• Product Name: (S)-2-AMINO-3-(4-HYDROXY-3-NITRO-PHENYL)-PROPIONIC ACID METHYL ESTER
• Synonyms: (S)-2-AMINO-3-(4-HYDROXY-3-NITRO-PHENYL)-PROPIONIC ACID METHYL ESTER;2-nitrotyrosine methyl ester;L-Tyrosine, 3-nitro-, Methyl ester
• CAS NO: 3195-65-1
• Molecular Formula: C₁₀H₁₂N₂O₅
• Molecular Weight: 240.21268
• Mol File: 3195-65-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 377.4°Cat760mmHg
• Flash Point: 182°C
• Appearance: /
• Density: 1.387g/cm³
• Vapor Pressure: 3.12E-06mmHg at 25°C
• Refractive Index: 1.594
• CAS DataBase Reference: (S)-2-AMINO-3-(4-HYDROXY-3-NITRO-PHENYL)-PROPIONIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-AMINO-3-(4-HYDROXY-3-NITRO-PHENYL)-PROPIONIC ACID METHYL ESTER(3195-65-1)
• EPA Substance Registry System: (S)-2-AMINO-3-(4-HYDROXY-3-NITRO-PHENYL)-PROPIONIC ACID METHYL ESTER(3195-65-1)

Safety Data

• Hazardous Substances Data: 3195-65-1(Hazardous Substances Data)

Usage

Description

(S)-2-AMINO-3-(4-HYDROXY-3-NITRO-PHENYL)-PROPIONIC ACID METHYL ESTER, with the molecular formula C11H13N3O5, is a methyl ester derivative of 2-amino-3-(4-hydroxy-3-nitrophenyl)propionic acid. It is a structural analog of the neurotransmitter glutamate, which plays a crucial role in the central nervous system. (S)-2-AMINO-3-(4-HYDROXY-3-NITRO-PHENYL)-PROPIONIC ACID METHYL ESTER is a potential pharmacological agent with significant implications in the field of neuroscience due to its ability to modulate glutamate receptor activity. Its structure suggests that it may exhibit similar biological activity to other glutamate analogs, indicating its potential therapeutic applications in the treatment of neurological disorders.

Uses

Used in Pharmaceutical Industry:
(S)-2-AMINO-3-(4-HYDROXY-3-NITRO-PHENYL)-PROPIONIC ACID METHYL ESTER is used as a pharmacological agent for its potential to modulate glutamate receptor activity. This modulation can be beneficial in the development of treatments for neurological disorders, as glutamate receptors are known to be involved in various brain functions and diseases.
Used in Research and Development:
In the field of neuroscience research, (S)-2-AMINO-3-(4-HYDROXY-3-NITRO-PHENYL)-PROPIONIC ACID METHYL ESTER serves as a valuable tool for studying the role of glutamate receptors in the central nervous system. Its structural similarity to glutamate allows researchers to investigate the mechanisms of receptor activation, inhibition, and signaling pathways, which can lead to a better understanding of neurological disorders and the development of novel therapeutic strategies.
Used in Drug Design and Development:
The potential therapeutic applications of (S)-2-AMINO-3-(4-HYDROXY-3-NITRO-PHENYL)-PROPIONIC ACID METHYL ESTER in the treatment of neurological disorders make it an important compound in drug design and development. Its unique structure and activity can be leveraged to create new drugs or improve existing ones, targeting specific neurological conditions and enhancing patient outcomes.

InChI:InChI=1/C10H12N2O5/c1-17-10(14)7(11)4-6-2-3-9(13)8(5-6)12(15)16/h2-3,5,7,13H,4,11H2,1H3/t7-/m0/s1

Upstream product

• 67-56-1 methanol 
• 621-44-3 3-nitro-L-tyrosine 
• 60-18-4 L-tyrosine 

Downstream Products

• 573968-33-9 (S)-2-((S)-2-tert-Butoxycarbonylamino-3-methyl-butyrylamino)-3-(4-hydroxy-3-nitro-phenyl)-propionic acid methyl ester 
• 573968-37-3 {3-[(S)-2-((S)-2-tert-Butoxycarbonylamino-3-methyl-butyrylamino)-3-oxo-propyl]-phenyl}-carbamic acid benzyl ester 
• 573968-36-2 (S)-3-(3-Benzyloxycarbonylamino-phenyl)-2-((S)-2-tert-butoxycarbonylamino-3-methyl-butyrylamino)-propionic acid methyl ester 
• 573968-38-4 C₅₇H₇₆N₆O₁₂ 
• 354820-63-6 (S)-methyl 3-(3-amino-4-hydroxyphenyl)-2-((tert-butoxycarbonyl)amino)propanoate 
• 591254-53-4 methyl N-(9-fluorenylmethoxycarbonyl)-3-nitro-L-tyrosinate 

Relevant articles and documents

Quantitative insight into the design of compounds recognized by the L-type amino acid transporter 1 (LAT1)

L-Type amino acid transporter 1 (LAT1) is a transmembrane protein expressed abundantly at the blood-brain barrier (BBB), where it ensures the transport of hydrophobic acids from the blood to the brain. Due to its unique substrate specificity and high expression at the BBB, LAT1 is an intriguing target for carrier- mediated transport of drugs into the brain. In this study, a comparative molecular field analysis (CoMFA) model with considerable statistical quality (Q2=0.53, R2=0.75, Q2 SE=0.77, R2 SE=0.57) and good external predictivity (CCC=0.91) was generated. The model was used to guide the synthesis of eight new prodrugs whose affinity for LAT1 was tested by using an in situ rat brain perfusion technique. This resulted in the creation of a novel LAT1 prodrug with l-tryptophan as the promoiety; it also provided a better understanding of the molecular features of LAT1-targeted high-affinity prodrugs, as well as their promoiety and parent drug. The results obtained will be beneficial in the rational design of novel LAT1-binding prodrugs and other compounds that bind to LAT1.

Calcilytic compounds

Novel calcilytic compounds, pharmaceuticals compositions cotaining said compounds and their use as calcium receptor antagonists.